 Corbus Pharmaceuticals NASDAQ:CRBP was downgraded by analysts at BidaskClub from a buy rating to a hold rating in a report released on Tuesday, BidAskClub reports. Other equities research analysts also recently issued research reports about the company. BTIG Research initiated coverage on Corbus Pharmaceuticals in a research report on Tuesday, June 16th. They set a ... 